Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stéphanie Bécourt
Observed names:
S Becourt,
S. Becourt,
S. Bécourt,
S. Mervoyer Becourt,
Stephanie Becourt,
Stéphanie Becourt
show all 6
Institution:
Centre Oscar Lambret
Observed institutions:
Assistance Publique – Hôpitaux de Paris,
Centre Oscar Lambret,
Hôpital Saint-Louis,
Université Paris Descartes
OpenAlex ID:
A5000040076
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
2024
·
Aditya Bardia
, Komal Jhaveri
, et al.
·
Journal of Clinical Oncology
·
271
PDF
Gynecologic symptoms and the influence on reproductive life in 386 women with hypermobility type ehlers-danlos syndrome: a cohort study
2016
·
Justine Hugon-Rodin
, Géraldine Lebègue
, et al.
·
Orphanet Journal of Rare Diseases
·
91
PDF
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
2024
·
F. Poumeaud
, M. Morisseau
, et al.
·
British Journal of Cancer
·
79
PDF
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
2025
·
Ursula A. Matulonis
, Jørn Herrstedt
, et al.
·
Gynecologic Oncology
·
55
Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints
2022
·
Delphine Hudry
, Solenn Le Guellec
, et al.
·
Cancers
·
43
PDF
Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)
2023
·
Ursula Matulonis
, Jørn Herrstedt
, et al.
·
Gynecologic Oncology
·
38
PDF
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
2023
·
Gwénaël Ferron
, Gaëtan De Rauglaudre
, et al.
·
Gynecologic Oncology
·
28
Abstract PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study
2024
·
François Poumeaud
, Mathilde Morisseau
, et al.
·
Cancer Research
·
21
The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
2022
·
François Cherifi
, Sophie Lefevre Arbogast
, et al.
·
Frontiers in Oncology
·
19
PDF
Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision—a Literature Review
2022
·
Delphine Hudry
, Stéphanie Bécourt
, et al.
·
Current Oncology Reports
·
17
#161 Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer
2023
·
Mansoor R Mirza
, Jørn Herrstedt
, et al.
·
International Journal of Gynecological Cancer
·
13
PDF
Prognostic impact of tumor size reduction assessed by magnetic resonance imaging after radiochemotherapy in patients with locally advanced cervical cancer
2022
·
Abel Cordoba
, Benedicte Durand
, et al.
·
Frontiers in Oncology
·
9
PDF
16 Months Follow Up of Patients’ Behavior and Mild COVID-19 Patterns in a Large Cohort of Cancer Patients During the Pandemic
2022
·
Nawale Hajjaji
, Kathleen Lepoutre
, et al.
·
Frontiers in Oncology
·
9
PDF
Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC
2020
·
Luca Campedel
, Paul Blanc-Durand
, et al.
·
Cancers
·
9
PDF
Comparison of clinicopathological (CP) features and outcome of breast cancers (BC) in BRCA-mutation carriers patients, with a family history without BRCA-mutation and with sporadic disease.
2018
·
Stephanie Becourt
, Odile Cohen-Haguenauer
, et al.
·
Journal of Clinical Oncology
·
6
Breast Cancer Prognosis in Young BRCA1/BRCA2 Mutation Carriers: A Retrospective Hospital-based Cohort Study
2024
·
F. Hego
, M. Barthoulot
, et al.
·
Clinical Oncology
·
4
312P Efficacy of sequential antibody-drug conjugates (ADCs) targeting topoisomerase-1 in HER2-low metastatic breast cancer (MBC): Updated results and additional analyses from the French multicenter retrospective ADC-low cohort
2025
·
F. Poumeaud
, M. Morisseau
, et al.
·
ESMO Open
·
3
PDF
Management of cancer treatment-related fatigue in advanced breast cancer patients: an expert committee’s opinion
2025
·
Stéphanie Bécourt
, Sophie Abadie-Lacourtoisie
, et al.
·
Frontiers in Oncology
·
2
PDF
44O Safety and efficacy results in patients who received dose modifications in the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial of mirvetuximab soravtansine vs investigator’s choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha expression
2024
·
S. Banerjee
, T. Van Gorp
, et al.
·
ESMO Open
·
2
PDF
Cancer lobulaire infiltrant : épidémiologie, histoire naturelle, principes thérapeutiques
2017
·
Marc Espié
, Stéphanie Bécourt
, et al.
·
Imagerie de la Femme
·
2
Y a-t-il une place pour la fimbriectomie radicale prophylactique suivie d’une ovariectomie différée ?
2025
·
Tom Fidlers
, Fabrice Narducci
, et al.
·
Bulletin du Cancer
·
1
181P Male breast cancer (MBC): Familial history (FH), clinicopathological (CP) characteristics, oncogenetic (OG) testing and outcome in a cohort of 98 patients (pts)
2023
·
S. Chretien
, E. Aymes
, et al.
·
ESMO Open
·
1
PDF
Toxicités sévères des immunothérapies du cancer
2018
·
L. Campedel
, S. Assoun
, et al.
·
Médecine Intensive Réanimation
·
1
PDF
Real-world use of pembrolizumab in early-stage triple-negative breast cancer: Data from the French Early Access Program
2026
·
A. de Nonneville
, J.S. Frenel
, et al.
·
The Breast
PDF
Advanced ovarian cancer in women aged ≥80 years: a retrospective single-center study
2026
·
Sophie Schoenen
, Carlos Martinez Gomez
, et al.
·
European Journal of Surgical Oncology
Show more works
View as search
Works count:
47
Citation count:
728
H-index:
11
I10-index:
11
Year
Topic
Type